It was also observed that the development of chemoresistance to platinum compounds in ovarian carcinomas leads to collateral appearance of arginine auxotrophy due to the downregulation of ASS [14], adding these tumours to the list of potential targets of arginine deprivation-based enzymotherapy. This evidence concerns the gene ASS1 and ovarian carcinoma.